Phosphodiesterase Inhibitors for Alzheimer’s Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Background: Preclinical studies, clinical trials, and reviews suggest increasing 3’,5’-cyclic adenosine monophosphate (cAMP) and 3’,5’-cyclic guanosine monophosphate (cGMP) with phosphodiesterase inhibitors is disease-modifying in Alzheimer’s disease (AD). cAMP/protein kinase A (PKA) and cGMP/protein kinase G (PKG) signaling are disrupted in AD. cAMP/PKA and cGMP/PKG activate cAMP response element binding protein (CREB). CREB binds mitochondrial and nuclear DNA, inducing synaptogenesis, memory, and neuronal survival gene (e.g., brain-derived neurotrophic factor) and peroxisome proliferator-activated receptor- γ coactivator-1 α (PGC1 α). cAMP/PKA and cGMP/PKG activate Sirtuin-1, which activates PGC1 α. PGC1 α induces mitochondrial biogenesis and antioxidant genes (e.g.,Nrf2) and represses BACE1. cAMP and cGMP inhibit BACE1-inducing NF κB and tau-phosphorylating GSK3β. Objective and Methods: We review efficacy-testing clinical trials, epidemiology, and meta-analyses to critically investigate whether phosphodiesteraseinhibitors prevent or treat AD. Results: Caffeine and cilostazol may lower AD risk. Denbufylline and sildenafil clinical trials are promising but preliminary and inconclusive. PF-04447943 and BI 409,306 are ineffective. Vinpocetine, cilostazol, and nicergoline trials are mixed. Deprenyl/selegiline trials show only short-term benefits. Broad-spectrum phosphodiesterase inhibitor propentofylline has been shown in five phase III trials to improve cognition, dementia severity, activities of daily living, and global assessment in mild-to-moderate AD patients on multiple scales, including the ADAS-Cogand the CIBIC-Plus in an 18-month phase III clinical trial. However, two books claimed based on a MedScape article an 18-month phase III trial failed, so propentofylline was discontinued. Now, propentofylline is used to treat canine cognitive dysfunction, which, like AD, involves age-associated wild-type Aβ deposition. Conclusion: Phosphodiesterase inhibitors may prevent and treat AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease
Cappello, V., Marchetti, L., Parlanti, P., Landi, S., Tonazzini, I., Cecchini, M., Piazza, V., & Gemmi, M. (2016) · Scientific Reports · doi:10.1038/s41598-016-0001-8 · Cited by 13,097
UniProt: the universal protein knowledgebase
The UniProt Consortium (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1099 · Cited by 4,436
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“This balancebetween mitochondrial biogenesis and mitophagy appears to be disrupted in AD patients’ hippocampal pyramidal neurons as shown by the PGC1 downregulation [93, 129], as well as the finding that many of the few surviving mitochondria accumulate in autophagosomes [22, 130].”
BackgroundMetabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC‐1α
Gerhart‐Hines, Z., Rodgers, J. T., Bare, O., Lerin, C., Kim, S., Mostoslavsky, R., Alt, F. W., Wu, Z., & Puigserver, P. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601633 · Cited by 1,294
Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide
Nisoli, E., Clementi, E., Paolucci, C., Cozzi, V., Tonello, C., Sciorati, C., Bracale, R., Valerio, A., Francolini, M., Moncada, S., et al. (2003) · Science · doi:10.1126/science.1079368 · Cited by 1,243
Regulation of pgc-1α, a nodal regulator of mitochondrial biogenesis
Fernandez-Marcos, P. J., & Auwerx, J. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.001917 · Cited by 1,237
Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS
Nisoli, E., Tonello, C., Cardile, A., Cozzi, V., Bracale, R., Tedesco, L., Falcone, S., Valerio, A., Cantoni, O., Clementi, E., et al. (2005) · Science · doi:10.1126/science.1117728 · Cited by 1,107
SIRT1 Functionally Interacts with the Metabolic Regulator and Transcriptional Coactivator PGC-1α
Nemoto, S., Fergusson, M. M., & Finkel, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501485200 · Cited by 1,047
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Exosomes maintain cellular homeostasis by excreting harmful DNA from cells
Takahashi, A., Okada, R., Nagao, K., Kawamata, Y., Hanyu, A., Yoshimoto, S., Takasugi, M., Watanabe, S., Kanemaki, M. T., Obuse, C., et al. (2017) · Nature Communications · doi:10.1038/ncomms15287 · Cited by 761
Expression of Nrf2 in Neurodegenerative Diseases
Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760
Luen Tang, B. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.2318 · Cited by 740
Readhead, B., Haure-Mirande, J.-V., Funk, C. C., Richards, M. A., Shannon, P., Haroutunian, V., Sano, M., Liang, W. S., Beckmann, N. D., Price, N. D., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.023 · Cited by 708
The release and trans-synaptic transmission of Tau via exosomes
Wang, Y., Balaji, V., Kaniyappan, S., Krüger, L., Irsen, S., Tepper, K., Chandupatla, R., Maetzler, W., Schneider, A., Mandelkow, E., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0143-y · Cited by 674
The Unfolded Protein Response Is Activated in Pretangle Neurons in Alzheimer's Disease Hippocampus
Hoozemans, J. J. M., van Haastert, E. S., Nijholt, D. A. T., Rozemuller, A. J. M., Eikelenboom, P., & Scheper, W. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080814 · Cited by 600
Colacurcio, D. J., & Nixon, R. A. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.05.004 · Cited by 548
Vitolo, O. V., Sant'Angelo, A., Costanzo, V., Battaglia, F., Arancio, O., & Shelanski, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172504199 · Cited by 534
Microbes and Alzheimer’s Disease
Itzhaki, R. F., Lathe, R., Balin, B. J., Ball, M. J., Bearer, E. L., Braak, H., Bullido, M. J., Carter, C., Clerici, M., Cosby, S. L., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160152 · Cited by 532
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Sardar Sinha, M., Ansell-Schultz, A., Civitelli, L., Hildesjö, C., Larsson, M., Lannfelt, L., Ingelsson, M., & Hallbeck, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1868-1 · Cited by 527
Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals
Nisoli, E., Falcone, S., Tonello, C., Cozzi, V., Palomba, L., Fiorani, M., Pisconti, A., Brunelli, S., Cardile, A., Francolini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405432101 · Cited by 495 · cited 1×
“PGC1 also induces genes involved in oxidative respiration [92, 103] and fatty acid -oxidation [120].”
BackgroundGong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442
TLR2 Is a Primary Receptor for Alzheimer’s Amyloid β Peptide To Trigger Neuroinflammatory Activation
Liu, S., Liu, Y., Hao, W., Wolf, L., Kiliaan, A. J., Penke, B., Rübe, C. E., Walter, J., Heneka, M. T., Hartmann, T., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101121 · Cited by 439
Chen, C.-H., Zhou, W., Liu, S., Deng, Y., Cai, F., Tone, M., Tone, Y., Tong, Y., & Song, W. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000149 · Cited by 433 · cited 13×
“BACE1 overexpression decreases cAMP levels, PKA activity, and CREB phosphorylation independently of A [199].”
BackgroundInfluentialNeuronal organization of olfactory bulb circuits
Nagayama, S., Homma, R., & Imamura, F. (2014) · Frontiers in Neural Circuits · doi:10.3389/fncir.2014.00098 · Cited by 411
Sensing of HSV-1 by the cGAS-STING pathway in microglia orchestrates antiviral defence in the CNS
Reinert, L. S., Lopušná, K., Winther, H., Sun, C., Thomsen, M. K., Nandakumar, R., Mogensen, T. H., Meyer, M., Vægter, C., Nyengaard, J. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms13348 · Cited by 397
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease
Lee, D. I., Zhu, G., Sasaki, T., Cho, G.-S., Hamdani, N., Holewinski, R., Jo, S.-H., Danner, T., Zhang, M., Rainer, P. P., et al. (2015) · Nature · doi:10.1038/nature14332 · Cited by 353 · cited 4×
“Clinical trials of PF-04447943 and BI 409,306 have shown a lack of efficacy [341, 342], which might be because PDE9 inhibition increases periplasma membrane cGMP (rather than cytoplasmic cGMP) and allows Ca2+ influx through CNG [68, 71, 213].”
BackgroundInfluentialBordi, M., Berg, M. J., Mohan, P. S., Peterhoff, C. M., Alldred, M. J., Che, S., Ginsberg, S. D., & Nixon, R. A. (2016) · Autophagy · doi:10.1080/15548627.2016.1239003 · Cited by 353 · cited 1×
“autophagy [31], neuroinflammation [32–38], neu-”
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Arendash, G. W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tan, J., Citron, B. A., Lin, X., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1087 · Cited by 308
Biochemistry of Tau in Alzheimer’s disease and related neurological disorders
Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., et al. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.207 · Cited by 300
Anderson, R. M., Barger, J. L., Edwards, M. G., Braun, K. H., O’Connor, C. E., Prolla, T. A., & Weindruch, R. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2007.00357.x · Cited by 283
Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment
Wang, J., Markesbery, W. R., & Lovell, M. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03615.x · Cited by 260
Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
Soares, H. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1070 · Cited by 218
The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer’s Disease
Hays, C. C., Zlatar, Z. Z., & Wierenga, C. E. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0261-z · Cited by 213
Tong, L., Thornton, P. L., Balazs, R., & Cotman, C. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010450200 · Cited by 206 · cited 1×
“Sublethal doses of A 42 (but not A 25–35) impair KCland N-methyl-D-aspartate-induced CREB phosphorylation [193].”
BackgroundMiklossy, J. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00046 · Cited by 203
Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease
Bradley, M. A., Markesbery, W. R., & Lovell, M. A. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.02.016 · Cited by 193
Gurd, B. J. (2011) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h11-070 · Cited by 171
Miklossy, J., Khalili, K., Gern, L., Ericson, R. L., Darekar, P., Bolle, L., Hurlimann, J., & Paster, B. J. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6608 · Cited by 163
Yang, J.-L., Lin, Y.-T., Chuang, P.-C., Bohr, V. A., & Mattson, M. P. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8270-x · Cited by 159
Rangasamy, S. B., Jana, M., Roy, A., Corbett, G. T., Kundu, M., Chandra, S., Mondal, S., Dasarathi, S., Mufson, E. J., Mishra, R. K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96209 · Cited by 139 · cited 3×
“Inflammatory NFκB is activated by oxidative stress [148], diverse pathogen- and damage-associated molecular patterns via toll-like receptors (TLR) [149, 150], fibrillar A via TLR2 [32], pro-inflammatory cytokines (e.g., TNF via the TNF receptor and IL-1 via the IL-1 receptor) [147], and other immunoreceptors [37, 148]…”
BackgroundKokot, A., Metze, D., Mouchet, N., Galibert, M.-D., Schiller, M., Luger, T. A., & Böhm, M. (2009) · Endocrinology · doi:10.1210/en.2008-1315 · Cited by 132
Alzheimer's disease pathology is attenuated in a CD 38‐deficient mouse model
Blacher, E., Dadali, T., Bespalko, A., Haupenthal, V. J., Grimm, M. O. W., Hartmann, T., Lund, F. E., Stein, R., & Levy, A. (2015) · Annals of Neurology · doi:10.1002/ana.24425 · Cited by 117
Nitric oxide activation of Keap1/Nrf2 signaling in human colon carcinoma cells
Li, C.-Q., Kim, M. Y., Godoy, L. C., Thiantanawat, A., Trudel, L. J., & Wogan, G. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907539106 · Cited by 108 · cited 1×
“In colon carcinoma cells, nitric oxide activated Nrf2 [146].”
BackgroundCoffee intake and decreased amyloid pathology in human brain
Kim, J. W., Byun, M. S., Yi, D., Lee, J. H., Jeon, S. Y., Jung, G., Lee, H. N., Sohn, B. K., Lee, J.-Y., Kim, Y. K., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0604-5 · Cited by 86
Driscoll, I., Shumaker, S. A., Snively, B. M., Margolis, K. L., Manson, J. E., Vitolins, M. Z., Rossom, R. C., & Espeland, M. A. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw078 · Cited by 55 · cited 1×
“In a 2016 study (n = 6,467), caffeine intake was associated with a lower risk of incident dementia and cognitive decline in women over the age of 65 [213, 364, 368].”
Background
Cited by
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
Kang, Y. J., Diep, Y. N., Tran, M., & Cho, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249591 · Cited by 36
“, phosphodiesterase type 4 inhibitor) [42], tau aggregation inhibitor (e.”
BackgroundLiu, J., Liu, L., Zheng, L., Feng, K.-W., Wang, H.-T., Xu, J.-P., & Zhou, Z.-Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114503 · Cited by 28
MicroRNA-Target Interaction Regulatory Network in Alzheimer’s Disease
Turk, A., Kunej, T., & Peterlin, B. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121275 · Cited by 20
Hasan, N., Zameer, S., Najmi, A. K., Parvez, S., & Akhtar, M. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00482-x · Cited by 17
“…these promising results, it is recommended that RFM be investigated further in other in vivo AD models as well as human subjects, with a focus on upstream components of the cAMP/BDNF signalling pathway, to confirm its anti-AD potential and present this PDE-4 inhibitor as an effective AD therapy.”
Retracted
Metadata
- Authors
- Sanders, O., & Rajagopal, L.
- Venue
- Journal of Alzheimer's Disease Reports
- Publisher
- SAGE Publications
- Published
- 2020-06-16
- Volume
- 4
- Issue
- 1
- Pages
- 185-215
- ISSN
- 2542-4823 (ISSN-L)
- OpenAlex
- W3036185152
- Cited by
- 113
- References
- 53
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.